Wilex, Telix deal

Wilex granted newco Telix exclusive, worldwide rights to develop and commercialize Redectane (124-iodine-girentuximab).

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE